References
1. Mcglynn KA, Petrick JL, London WT. Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. Clin Liver Dis. 2015; 19 (2): 223-38.
2. Forner A, Reig M, Bruix J. Hepatocelullar carcinoma. Lancet. 2018; 391: 1301–14.
3. INCA – Ministério da Saúde. Dados de Incidência de Câncer no Brasil – Estimativa 2018. [Internet] 2018. Available from: http://www.inca.gov.br/estimativa/2018/estimativa-2018.pdf
4. Díaz-González A, Forner A, Rodríguez-de-Lope C, et al. New challenges in clinical research on hepatocellular carcinoma. Rev Esp Enferm Dig. 2016;108(8):485-493.
5. Maiorov EG, Keskin O, Gursoy A, et al. The structural network of inflammation and cancer: Merits and challenges. Semin Cancer Biol. 2013; 23(4): 243-251.
6. Budhu A, Wang XW. The role of cytokines in hepatocellular carcinoma. J Leukoc Biol. 2006; 80(6): 1197-213.
7. Fernandes JV, Cobucci RN, Jatobá CAN, et al. The role of the mediators of inflammation in cancer development. Pathol Oncol Res. 2015; 21(3): 527-34.
8. Capece D, Fischietti M, Verzella D, et al. The inflammatory microenvironment in hepatocellular carcinoma: a pivotal role for tumor-associated macrophages. Biomed Res Int. 2013; 2013:187204.
9. Abbas AK, Lichtman AH. Imunologia básica: funções e distúrbios do sistema imunológico. 3th ed. Rio de Janeiro: Elsevier; 2009. p. 273-8.
10. Thompson PA, Khatami M, Baglole CJ, et al. Environmental immune disruptors, inflammation and cancer risk. Carcinogenesis. 2015; 36 Suppl 1: S232-53.
11. Turculeanu A, Mongoanta CA, Ionita E, et al. TNF-α evaluation in tonsil cancer. Rom J Morphol Embryol. 2015; 56(1): 101-6.
12. Al obeed OA, Alkhayal KA, Al Sheikh A, et al. Increased expression of tumor necrosis factor-α is associated with advanced colorectal cancer stages. World J Gastroenterol. 2014; 20(48): 18390-6.
13. Hammam O, Mahmoud O, Zahran M, et al. A possible role for TNF-α in coordinating inflammation and angiogenesis in chronic liver disease and hepatocellular carcinoma. Gastrointest Cancer Res. 2013; 6(4): 107-114.
14. Szabo G, Lippai D. Molecular hepatic carcinogenesis: Impact of inflammation. Dig Dis. 2012; 30: 243-8
15. Gosh N, Chaki R, Mandal V, et al. COX-2 as a target for cancer chemotherapy. Pharmacol Rep. 2010; 62(2):233-44.
16. Cheng J, Fan X-M. Role of cyclooxygenase-2 in gastric cancer development and progression. World J Gastroenterol. 2013; 19(42): 7361-7368.
17. Cruzs SM, Balkwill FR. Inflammation and cancer: advances and new agents. Nat Rev Clin Oncol. 2015; 12(10):584-96.
18. Chen J, Wu F, Pei H-L, et al. Analysis of the correlation between P53 and Cox-2 expression and prognosis in esophageal cancer. Oncol Lett. 2015; 10(4): v2197-203.
19. Giannitrapani L, Ingrao S, Soresi M, et al. Cyclooxygenase-2 expression in chronic liver diseases and hepatocellular carcinoma. Ann N Y Acad Sci. 2009; 1155: 293-9.
20. Cheng AS-L, Chan HL-Y, Leung WK, et al. Expression of HBx and COX-2 in chronic hepatitis B, cirrhosis and hepatocellular carcinoma: implication of HBx in up-regulation of COX-2. Modern Pathology. 2004; 17: 1169-79.
21. Bae SH, Jung ES, Park YM, et al. Expression of cyclooxygenase-2 (COX-2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a COX-2 inhibitor, NS-3981. Clin Cancer Res. 2001; 7(5):1410-8.
22. Koga H, Sakisaka S, Ohishi M, et al. Expression of cyclooxygenase-2 in human hepatocellular carcinoma: Relevance to tumor dedifferentiation. Hepatology. 1999; 29(3):688-96.
23. Kalra, M, Mayes J, Assefa S, et al. Role of sex steroid receptors in pathobiology of hepatocellular carcinoma. World J Gastroenterol. 2008; 14(39): 5945-61.
24. Zhai Y, Zhou G, Deng G, et al. Estrogen receptor alpha polymorphisms associated with susceptibility to hepatocellular carcinoma in hepatitis B virus carriers. Gastroenterology. 2006; 130: 2001-9.
25. Shi L, Feng Y, Lin H, et al. Role of estrogen in hepatocellular carcinoma: is inflammation the key? J. transl. med. 2014; 12: 1-9.
26. Baumgarten SC, Frasor J. Mini-review: Inflammation: An instigator of more aggressive estrogen receptor (ER)-positive breast cancers. Mol. endocrinol. 2012; 26(3): 360-371.
27. Kwon SH, Jeong SW, Jang JY, et al. Cyclooxygenase-2 and vascular endothelial growth factor in chronic hepatitis, cirrhosis and hepatocellular carcinoma. Clin Mol Hepatol. 2012; 18(3):287-94.
28. Yang Y, Zhu J, Gou H, et al. Clinical significance of Cox-2, Survivin and Bcl-2 expression in hepatocellular carcinoma (HCC). Med Oncol. 2011; 28: 796–803.
29.Jin Y, Chen J, Feng Z, et al. The expression of Survivin and NF-κB associated with prognostically worse clinicopathologic variables in hepatocellular carcinoma. Tumor Biol. 2014; 35: 9905–9910.
30.Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem. 1981; 29(4):577-80.
31. Weidner N, Semple JP, Welch WR, et al. Tumor angiogenesis and metastasis – correlation in invasive breast carcinoma. N Engl J Med. 1991; 324(1):1-8.
32. Mandarim-de-Lacerda CA. Stereological tools in biomedical research. An Acad Bras Cienc. 2003; 75(4):469-86.
33. Lin F, Chen Z. Standardization of Diagnostic Immunohistochemistry. Arch Pathol Lab Med. 2014; 138:1564–1577.
34. Chodbury KR, Yagle KJ, Swanson PE, et al. A robust automated measure of average antibody staining in immunohistochemistry images. J Histochem Cytochem. 2010; 58(2):95-107.
35. Brey EM, Lalani Z, Johnston C, et al. Automated selection of DAB-labeled Tissue for Immunohistochemical Quantification. J Histochem Cytochem. 2003; 51(5):575-84.
36. Ruifrok AC, Johnston DA. Quantification of histochemical staining by color deconvolution. Anal Quant Cytol Histol. 2001; 23(4):291-9.
37. Buendia MA, Neuveut C. Hepatocellular carcinoma. Cold Spring Harb Perspect Med. 2015; 5(2): 021444.
38. Yang JD, Roberts LR. Hepatocellular carcinoma: a global view. Nat. Rev. Gastroenterol. Hepatol. 2010; 7:448–458.
39. CEVS - Rio Grande do Sul. Panorama das Hepatites Virais no Estado do Rio Grande do Sul, Brasil. [Internet] 2018. Available from: https://cevs.rs.gov.br/upload/arquivos/201807/25114428-panorama-das-hepatites-virais-b-e-c-no-rs.pdf.
40. Appel-da-Silva MC, Miozzo SAS, Dossin IA, et al. Incidence of hepatocellular carcinoma in outpatients with cirrhosis in Brazil: A 10-year retrospective cohort study. World J Gastroenterol. 2016; 22(46): 10219–10225.
41. Kikichu L, Chagas AL, Alencar RSSM, et al. Clinical and epidemiological aspects of hepatocellular carcinoma in Brazil. Antivir Ther. 2013;18(3 Pt B):445-9.
42. Kew MC. The role of cirrhosis in the etiology of hepatocellular carcinoma. J Gastrointest Cancer. 2014; 45 (1): 12-21.
43.Birgani MT, Carloni V. Tumor microenvironment, a paradigm in hepatocellular carcinoma progression and therapy. Int J Mol Sci. 2017; 18(2): 1-19.
44. Shimizu I, Kohno N, Tamaki K, et al. Female hepatology: Favorable role of estrogen in chronic liver disease with hepatitis B virus infection. World J Gastroenterol. 2007; 13(32): 4295-4305.
45. Visozo FJ, Rodriguez M, Altadill A, et al. Liver expression of steroid hormones and Apolipoprotein D receptors in hepatocellular carcinoma. World J Gastroenterol. 2007; 13(23): 3221-3227.
46. Hong EJ, Levasseur MP, Dufour CR, et al. Loss of estrogen-related receptor α promotes hepatocarcinogenesis development via metabolic and inflammatory disturbances. Proc Natl Acad Sci U S A. 2013; 110(44):17975-80.
47. Cui W, Yu CH, Hu KQ. In vitro and in vivo effects and mechanisms of celecoxib-induced growth inhibition of human hepatocellular carcinoma cells. Clin Cancer Res. 2005; 11(22):8213-21.
48. Morisaki T, Umebayashi M, Kiyota A, et al. Combining celecoxib with sorafenib synergistically inhibits hepatocellular carcinoma cells in vitro. Anticancer Res. 2013; 33(4):1387-95.
49. Wang H, Liu J, Hu X, et al. Prognostic and therapeutic values of tumor necrosis factor-alpha in hepatocellular carcinoma. Med Sci Monit. 2016; 22: 3694-3704.
50. Dong Y, Liu Y, Kou X, et al. The protective or damaging effect of Tumor necrosis factor‑α in acute liver injury is concentration‑dependent. Cell Biosci. 2016; 6 (8): 1-10.